AFFLUENT MEDICAL Affluent Medical : Availability of the Universal Registration Document Universal Registration Document (URD) 2022

Transparency directive : regulatory news

26/04/2023 20:00

Affluent Medical
Affluent Medical : Availability of the Universal Registration Document Universal Registration Document (URD) 2022

26-Apr-2023 / 20:00 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Availability of the Universal Registration Document
Universal Registration Document (URD) 2022

Aix-en-Provence, April 26, 2023 - 8:00 pm CET- Affluent Medical (ISIN code: FR0013333077 – ticker: AFME), a French MedTech specializing in the international development and industrialization of innovative medical prostheses, at a clinical stage, to treat mitral heart valve pathology and urinary incontinence, announces today the availability to the public of its 2022 Universal Registration Document (URD), filed with the Autorité des marchés financiers (AMF) on April 26, 2023, under visa number R.23-019.

This document, which is available to the public free of charge under the conditions provided for by the regulations in force, can be consulted on the company's website www.affluentmedical.com (Investor Relations/Financial Documentation), as well as on that of the AMF (www.amf-france.org).
The 2022 Universal Registration Document has been prepared in the European Single Electronic Format (ESEF) in XBRL and includes:
- the 2022 annual financial report, consisting of the management report, the corporate governance report and the parent company and consolidated financial statements for the year ended December 31, 2022;
- the statutory auditors' reports and information on their fees;
- a description of the share buyback program.
An English version of the 2022 Universal Registration Document will be made available shortly.

About Affluent Medical
Affluent Medical is a French MedTech company, founded by Truffle Capital, with the ambition to become a global leader in the treatment of structural heart diseases, which are the world's leading cause of mortality, and urinary incontinence which currently affects one in four adults.
Affluent Medical develops next-generation, mini-invasive, innovative, adjustable, and biomimetic implants to restore critical physiological functions. The product candidates developed by the Company are currently in preclinical and clinical studies.
Kalios^TM, the first mitral adjustable annuloplasty ring, should be the first Affluent Medical device to be marketed.
Subject to raising the necessary funds to finance its strategy and to positive results from ongoing clinical studies, the Company's ambition is to progressively commercialize its products starting in 2025.
For more information: www.affluentmedical.com

Contacts:

AFFLUENT MEDICAL
Sébastien Ladet
Chief Executive Officer
investor@affluentmedical.com

ACTIFIN, financial communications
Ghislaine Gasparetto
+33 (0)6 21 10 49 24
affluentmedical@actifin.fr

ACTIFIN, financial press relations

Jennifer Jullia

+33 (0)1 56 88 11 19

jjullia@actifin.fr

PRIMATICE, public relations France
Thomas Roborel de Climens
+33 (0)6 78 12 97 95
thomasdeclimens@primatice.com

Regulatory filing PDF file

File: Availability of the Universal Registration Document Universal Registration Document (URD) 2022


Language:	English
Company:	Affluent Medical
	320 avenue Archimède, Les pléiades III Bâtiment B
	13100 Aix en Provence France
	France
Phone:	+33 4 42 95 12 20
E-mail:	jerome.geoffroy@affluentmedical.com
Internet:	https://www.affluentmedical.com/
ISIN:	FR0013333077
Euronext Ticker:	AFME
AMF Category:	Additional regulated information to be pubicly disclosed under the legislation of a Member State / Terms of availability of a registration document or its updates
EQS News ID:	1618319


End of Announcement	EQS News Service

1618319 26-Apr-2023 CET/CEST

AFFLUENT MEDICAL's latest news

25/04/2024 17:45

AFFLUENT MEDICAL Affluent Medical : Availability of the Universal Registration Document Universal Registration Document (URD) 2022

Transparency directive : regulatory news

Jennifer Jullia

+33 (0)1 56 88 11 19

AFFLUENT MEDICAL's latest news

Other stories